RegulatoryCompany release
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
Noema Pharma's oral mGluR5 modulator, already on the FDA's Fast Track, now also carries orphan status for the rare and painful neuropathic condition.
The US Food and Drug Administration has granted orphan drug designation to basimglurant, Noema Pharma's investigational treatment for trigeminal neuralgia. The Swiss company announced the decision on 16 November 2026. The compound was formerly known as NOE-101.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Noema Pharma AG ↗
Article written by VigiEye from the official source (Noema Pharma AG). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026
Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval
🇺🇸 Larimar Therapeutics, Inc. (LRMR) · Mon 16 Nov 2026